Between The Lines


Incorporating Real-World Evidence into Clinical Decisions in NSCLC

October 21st 2021

Considerations for referring to clinical trial data and real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer based on a recent publication by Nazha B, et al.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

October 15th 2021

Key takeaways from a recent study of tipifarnib as treatment for recurrent and/or metastatic mHRAS head and neck squamous cell carcinoma.

Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers

October 8th 2021

Experts collaborate to share and reflect on data from an eNRGy1 global registry study, which analyzed therapy in NRG1 fusion–driven lung cancers.

Circulating Tumor DNA as a Biomarker of Progression in Colorectal Cancer

October 8th 2021

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” and consider how to apply the paper’s findings into clinical practice.

PET/CT–Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

September 13th 2021

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, provide insight on the results and clinical implications of the EMPIRE-1 trial in prostate cancer.

Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors

August 24th 2021

In this program, George Ansstas, MD, and Firas B. Badin, MD, discuss a recently published paper on ctDNA for analysis of immunotherapy efficacy in individual patients with solid tumor malignancies.

Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions

August 20th 2021

In this program, D. Ross Camidge, MD, PhD, and Alexander Spira, MD, PhD, discuss a recently published paper on the anti-HER3 monoclonal antibody seribantumab in the treatment of tumor samples with oncogenic NRG1 fusions.

Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to A Pandora’s Box

August 9th 2021

In this journal club-like program, Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss a recently published paper about third-line treatments for HER2-positive breast cancer and provide insight about its implications for clinical practice.